FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306757048> ?p ?o ?g. }

• W4306757048 endingPage "77" @default.
• W4306757048 startingPage "68" @default.
• W4306757048 abstract "Long-term survival in patients with acute myeloid leukemia (AML) remains low, and current treatment modalities are inadequate. Milademetan (DS-3032, RAIN-32), a small-molecule specific murine double minute 2 inhibitor, has shown a p53 status-dependent antitumor effect in vitro studies. This is the first phase I study report of milademetan monotherapy in relapsed/refractory (R/R) AML patients evaluating the safety, tolerability, pharmacokinetics, and preliminary tumor response for further clinical development. Fourteen patients received 90 (starting dose, n = 4), 120 (n = 6), or 160 mg (n = 4) of oral milademetan once daily in a 14/28 treatment cycle. The median total treatment duration was 1.5 cycles. Dose-limiting toxicity did not occur, and the maximum tolerated dose was not reached. Thus, the recommended dose was defined as 160 mg. The most common adverse events (AEs) were decreased appetite (64.3%), febrile neutropenia (50%), nausea (42.9%), and anemia (35.7%). No deaths or AEs leading to treatment discontinuation occurred. Five serious treatment-emergent AEs occurred in 4 patients. Plasma concentration increased linearly with milademetan dose. However, trends in the safety and efficacy of oral milademetan in patients with R/R AML warrant further clinical investigation. This study can inform future milademetan studies in hematologic malignancies." @default.
• W4306757048 created "2022-10-19" @default.
• W4306757048 creator A5009129570 @default.
• W4306757048 creator A5021004681 @default.
• W4306757048 creator A5030597247 @default.
• W4306757048 creator A5034993943 @default.
• W4306757048 creator A5037216855 @default.
• W4306757048 creator A5050799385 @default.
• W4306757048 creator A5062668386 @default.
• W4306757048 creator A5066039877 @default.
• W4306757048 creator A5080396833 @default.
• W4306757048 creator A5080623389 @default.
• W4306757048 creator A5091537547 @default.
• W4306757048 date "2022-10-19" @default.
• W4306757048 modified "2023-10-17" @default.
• W4306757048 title "Phase I dose-escalation study of milademetan in patients with relapsed or refractory acute myeloid leukemia" @default.
• W4306757048 cites W1992947288 @default.
• W4306757048 cites W1994852323 @default.
• W4306757048 cites W2051445765 @default.
• W4306757048 cites W2061263203 @default.
• W4306757048 cites W2097933346 @default.
• W4306757048 cites W2113370608 @default.
• W4306757048 cites W2256505962 @default.
• W4306757048 cites W2303493284 @default.
• W4306757048 cites W2553673589 @default.
• W4306757048 cites W2958197380 @default.
• W4306757048 cites W2959680137 @default.
• W4306757048 cites W2988050604 @default.
• W4306757048 cites W2995587299 @default.
• W4306757048 cites W3004815730 @default.
• W4306757048 cites W3012293314 @default.
• W4306757048 cites W3012729910 @default.
• W4306757048 cites W3133661084 @default.
• W4306757048 cites W4247685543 @default.
• W4306757048 doi "https://doi.org/10.1007/s12185-022-03464-z" @default.
• W4306757048 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36258088" @default.
• W4306757048 hasPublicationYear "2022" @default.
• W4306757048 type Work @default.
• W4306757048 citedByCount "3" @default.
• W4306757048 countsByYear W43067570482023 @default.
• W4306757048 crossrefType "journal-article" @default.
• W4306757048 hasAuthorship W4306757048A5009129570 @default.
• W4306757048 hasAuthorship W4306757048A5021004681 @default.
• W4306757048 hasAuthorship W4306757048A5030597247 @default.
• W4306757048 hasAuthorship W4306757048A5034993943 @default.
• W4306757048 hasAuthorship W4306757048A5037216855 @default.
• W4306757048 hasAuthorship W4306757048A5050799385 @default.
• W4306757048 hasAuthorship W4306757048A5062668386 @default.
• W4306757048 hasAuthorship W4306757048A5066039877 @default.
• W4306757048 hasAuthorship W4306757048A5080396833 @default.
• W4306757048 hasAuthorship W4306757048A5080623389 @default.
• W4306757048 hasAuthorship W4306757048A5091537547 @default.
• W4306757048 hasBestOaLocation W43067570481 @default.
• W4306757048 hasConcept C112705442 @default.
• W4306757048 hasConcept C121332964 @default.
• W4306757048 hasConcept C126322002 @default.
• W4306757048 hasConcept C142424586 @default.
• W4306757048 hasConcept C194409129 @default.
• W4306757048 hasConcept C197934379 @default.
• W4306757048 hasConcept C2777063308 @default.
• W4306757048 hasConcept C2778248108 @default.
• W4306757048 hasConcept C2778375690 @default.
• W4306757048 hasConcept C2778715236 @default.
• W4306757048 hasConcept C2778729363 @default.
• W4306757048 hasConcept C2778850193 @default.
• W4306757048 hasConcept C2780580376 @default.
• W4306757048 hasConcept C29730261 @default.
• W4306757048 hasConcept C71924100 @default.
• W4306757048 hasConcept C87355193 @default.
• W4306757048 hasConcept C90924648 @default.
• W4306757048 hasConceptScore W4306757048C112705442 @default.
• W4306757048 hasConceptScore W4306757048C121332964 @default.
• W4306757048 hasConceptScore W4306757048C126322002 @default.
• W4306757048 hasConceptScore W4306757048C142424586 @default.
• W4306757048 hasConceptScore W4306757048C194409129 @default.
• W4306757048 hasConceptScore W4306757048C197934379 @default.
• W4306757048 hasConceptScore W4306757048C2777063308 @default.
• W4306757048 hasConceptScore W4306757048C2778248108 @default.
• W4306757048 hasConceptScore W4306757048C2778375690 @default.
• W4306757048 hasConceptScore W4306757048C2778715236 @default.
• W4306757048 hasConceptScore W4306757048C2778729363 @default.
• W4306757048 hasConceptScore W4306757048C2778850193 @default.
• W4306757048 hasConceptScore W4306757048C2780580376 @default.
• W4306757048 hasConceptScore W4306757048C29730261 @default.
• W4306757048 hasConceptScore W4306757048C71924100 @default.
• W4306757048 hasConceptScore W4306757048C87355193 @default.
• W4306757048 hasConceptScore W4306757048C90924648 @default.
• W4306757048 hasFunder F4320321625 @default.
• W4306757048 hasIssue "1" @default.
• W4306757048 hasLocation W43067570481 @default.
• W4306757048 hasLocation W43067570482 @default.
• W4306757048 hasLocation W43067570483 @default.
• W4306757048 hasOpenAccess W4306757048 @default.
• W4306757048 hasPrimaryLocation W43067570481 @default.
• W4306757048 hasRelatedWork W130051642 @default.
• W4306757048 hasRelatedWork W189281016 @default.
• W4306757048 hasRelatedWork W1945820803 @default.
• W4306757048 hasRelatedWork W2000475715 @default.

• next